Publications by authors named "Paul Brunetta"

Claim this Profile
D
Digital Smoking Cessation Preferences of Predominately Low-Income and Latino Residents of the San Joaquin Valley in California: Qualitative Study.
Karla D Llanes, Maya Vijayaraghavan, Sara Schneider, Pamela M Ling, Evi Hernandez, Paul Brunetta

JMIR Form Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Key considerations for advancing chimeric antigen receptor (CAR) T-cell therapy for systemic lupus erythematosus (SLE): a multi-partner/disciplinary working group perspective.
Elena W Y Hsieh, James B Chung, Afsah Amin, Anca D Askanase, Beatrix Bartok, Paul Brunetta

RMD Open· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Initial Evaluation of Acceptability, Engagement, and Effectiveness of the MO App to Provide Tailored and Comprehensive Support for Smoking Cessation: Development and Usability Study.
Shuo Zhou, Paul Brunetta, Joshva Silvasstar, Greg Feldman, Nicolas Oromi

JMIR Mhealth Uhealth· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autoreactive Plasmablasts After B Cell Depletion With Rituximab and Relapses in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Alvise Berti, Sophie Hillion, Maximilian F Konig, Marta Casal Moura, Amber M Hummel, Paul Brunetta

Arthritis Rheumatol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase IIa Global Study Evaluating Rituximab for the Treatment of Pediatric Patients With Granulomatosis With Polyangiitis or Microscopic Polyangiitis.
Paul Brogan, Rae S M Yeung, Gavin Cleary, Satyapal Rangaraj, Ozgur Kasapcopur, Paul Brunetta

Arthritis Rheumatol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial.
Richard A Furie, Gustavo Aroca, Matthew D Cascino, Jay P Garg, Brad H Rovin, Paul Brunetta

Ann Rheum Dis· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating autoreactive proteinase 3+ B cells and tolerance checkpoints in ANCA-associated vasculitis.
Alvise Berti, Sophie Hillion, Amber M Hummel, Young Min Son, Nedra Chriti, Paul Brunetta

JCI Insight· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fc receptor-like 5 and anti-CD20 treatment response in granulomatosis with polyangiitis and microscopic polyangiitis.
Kasia Owczarczyk, Matthew D Cascino, Cecile Holweg, Gaik W Tew, Ward Ortmann, Paul Brunetta

JCI Insight· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Andreas Kronbichler, Johannes Leierer, Jae Il Shin, Peter A Merkel, Robert Spiera, Paul Brunetta

Arthritis Rheumatol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant.
Robert R Redfield, Stanley C Jordan, Stephan Busque, Flavio Vincenti, E Steve Woodle, Paul Brunetta

Am J Transplant· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome of participants with nephrotic syndrome in combined clinical trials of lupus nephritis.
Liliana Michelle Gomez Mendez, Matthew D Cascino, Tamiko R Katsumoto, Paul Brakeman, Paul Brunetta

Lupus Sci Med· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis.
Liliana Michelle Gomez Mendez, Matthew D Cascino, Jay Garg, Tamiko R Katsumoto, Paul Brakeman, Paul Brunetta

Clin J Am Soc Nephrol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Alvise Berti, Roscoe Warner, Kent Johnson, Divi Cornec, Darrell Schroeder, Paul Brunetta

Arthritis Rheumatol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event.
Joseph R Berger, Vineeta Malik, Stuart Lacey, Paul Brunetta, Patricia B Lehane

J Neurovirol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event.
Joseph R Berger, Vineeta Malik, Stuart Lacey, Paul Brunetta, Patricia B Lehane

J Neurovirol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis.
Divi Cornec, Brian F Kabat, John R Mills, Melissa Cheu, Amber M Hummel, Paul Brunetta

Rheumatology (Oxford)· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cumulative oral corticosteroid use increases risk of glucocorticoid-related adverse events in patients with newly diagnosed pemphigus.
David Wormser, Diana M Chen, Paul G Brunetta, Diana Sun, Michael S Broder

J Am Acad Dermatol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Zachary S Wallace, Eli M Miloslavsky, Matthew Cascino, Sebastian H Unizony, Na Lu, Paul Brunetta

Arthritis Care Res (Hoboken)· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis.
Eli M Miloslavsky, Ray P Naden, Johannes W J Bijlsma, Paul A Brogan, E Sherwood Brown, Paul Brunetta

Ann Rheum Dis· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Pharmacogenomic Association of Fcγ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Rodrigo Cartin-Ceba, Divya Indrakanti, Ulrich Specks, John H Stone, Gary S Hoffman, Paul G Brunetta

Arthritis Rheumatol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
Sebastian Unizony, Miguel Villarreal, Eli M Miloslavsky, Na Lu, Peter A Merkel, Paul Brunetta

Ann Rheum Dis· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.
Duvuru Geetha, Ulrich Specks, John H Stone, Peter A Merkel, Philip Seo, Paul Brunetta

J Am Soc Nephrol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE.
William P Kennedy, Romeo Maciuca, Kristen Wolslegel, Wei Tew, Alexander R Abbas, Paul Brunetta

Lupus Sci Med· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximab.
Duvuru Geetha, Cees Kallenberg, John H Stone, Alan D Salama, Gerald B Appel, Paul Brunetta

J Nephrol· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of remission-induction regimens for ANCA-associated vasculitis.
Ulrich Specks, Peter A Merkel, Philip Seo, Robert Spiera, Carol A Langford, Paul Brunetta

N Engl J Med· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis